Form 4: Catalyst Pharmaceuticals Executive Vice President & CFO Acquires Shares and Options

Catalyst Pharmaceuticals' Executive Vice President & CFO, Michael Wayne Kalb, acquired 169,248 stock options and 20,682 restricted stock units on November 21, 2024.

Summary

• Michael Wayne Kalb, Executive Vice President & CFO of Catalyst Pharmaceuticals, acquired 169,248 options to purchase common stock at a price of $21.12 on November 21, 2024.
• These options vest in three equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027.
• Kalb also acquired 20,682 restricted stock units on the same date, which represent a contingent right to receive one share of common stock upon vesting.
• Following these transactions, Kalb directly owns 462,155 shares of common stock and 482,837 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options and restricted stock units by a key executive demonstrates confidence in the company's future performance.
• The vesting schedule of the options and restricted stock units aligns the executive's interests with the long-term success of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives acquire or dispose of company securities. It provides transparency into insider transactions.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are a common form of executive compensation in the pharmaceutical industry.
• The vesting schedule of the options is typical, aligning executive incentives with long-term company performance.
• The number of options and restricted stock units granted is within the range of what is seen in similar companies.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by the CFO may be viewed positively by shareholders as it indicates confidence in the company's future performance.
• The vesting schedule of the options and restricted stock units aligns the executive's interests with the long-term success of the company, which is beneficial for shareholders.

Key Dates

Keywords

Catalyst Pharmaceuticals, Executive Compensation, Stock Options, Restricted Stock Units, Insider Trading, Form 4, CPRX, Michael Wayne Kalb